In the past 15 years, antioxidants have soared on promises that remained mostly unfulfilled, and crashed on doubts that were overstated. Where do antioxidants fit today in the palette of functional ingredients?
A new published study finds a direct link between the length of telomeres, the end-caps of DNA, and increased risks of heart attack and death. Find out what science-backed ingredients are tops when it comes to slowing cellular aging, and the companies that are formulating with them.
A new study by the National Institutes of Health sheds light on the action of resveratrol in cells. One resveratrol supplier has hailed the results, while another believes it promotes a pharmaceutical application, as opposed to a dietary supplement.
The Council for Responsible Nutrition (CRN) recently discussed its concerns about the New Dietary Ingredients draft guidance with the FDA. Although the issue has inflamed industry, CRN President Steve Mister said it is still possible to negotiate with the agency.
The natural industry has reacted strongly to a New England Journal of Medicine article calling for FDA premarket approval of dietary supplements. Should responsible supplement manufacturers be punished because of a few rogue companies that sell adulterated products?
Recently on the Dr. Oz Show, a series of weight loss supplements were tested and found adulterated with undeclared pharmaceutical ingredients. The guest who conducted the tests, however, believes industry and FDA have the tools to make things better.
Sens. Orrin Hatch and Tom Harkin have called on FDA to immediately withdraw its draft NDI guidance. The senators said the guidance does not match their intent when they wrote DSHEA, and asked for a meeting soon with FDA to discuss a rewrite of the guidance.
The comments are in and the dietary supplement industry's verdict is clear: The NDI draft guidance is so flawed that a complete rewrite is needed, and FDA should withdraw the guidance now, so that it is clear the the document will not be used as a basis for enforcement in the interim.
In comments submitted Nov. 30 to FDA, the Natural Products Association calls on the government agency to rewrite the NDI guidance document to make the filing process pertain to ingredients, not finished products. Here's a briefing of how the NPA would clarify NDI guidance.